

IMMUNO-ONCOLOGY SYMPOSIUM

ESMO Symposium on Immuno-Oncology Programme book

Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies

Geneva Switzerland

15-16 NOVEMBER 2013

SYMPOSIUM PROGRAMME

Friday, 15 November 2013

10:00	Welcome coffee
10:30/ 10:45	Welcome George Coukos, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland
10:45/ 11:45	The role of the immune system in cancer Chairs: George Coukos, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland
10:45	Engineering T cells to overcome tolerance Carl H. June, Philadelphia, PA, US
11:15	Checkpoint blockade Ignacio Melero, Pamplona, Spain
11:45/ 13:15	Immuno-Oncology clinical studies across tumour types I Chair: Martin Gore, London, UK
11:45	Melanoma as proof of concept Olivier Michielin, Lausanne, Switzerland
12:10	Prostate cancer Winald Gerritsen, Amsterdam, Netherlands
12:35	Renal cancer Martin Gore, London, UK
13:00	General discussion / Q&A
13:15	Lunch
14:15/ 16:00	Immuno-Oncology clinical studies across tumour types II Chair: George Coukos, Lausanne, Switzerland
14:15	Lung cancer: Vaccination approaches Johan Vansteenkiste, Leuven, Belgium
14:35	Lung cancer: Other Scott J. Antonia, Tampa, FL, US
14:55	Ovarian cancer George Coukos, Lausanne, Switzerland
15:20	Brain tumours Pierre-Yves Dietrich, Geneva, Switzerland
15:45	General discussion / Q&A
16:00	Coffee break

16:30/ 17:05	Immune checkpoint inhibitors Chair: Solange Peters, Lausanne, Switzerland	
16:30	Two cases of immunotherapy with monoclonal antibodies <i>Ignacio Melero, Pamplona, Spain</i>	
16:45	Case report of a serious adverse event upon administration of T cells transduced with a MART-1 specific T cell receptor Joost van den Berg, Amsterdam, Netherlands	
16:55	General discussion / Q&A	
17.05/	Clinical avacuiones and management of violubonofit	
17:05/ 17:50	Clinical experience and management of risk:benefit Chair: Olivier Michielin, Lausanne, Switzerland	
17:05	Panel Discussion Rolf A.Stahel, Zurich, Switzerland George Coukos, Lausanne, Switzerland Solange Peters, Lausanne, Switzerland	
17:50	Cocktail	

Saturday, 16 November 2013

08:30/ 10:25	Implications for clinical practice Chair: Jedd D. Wolchok, New York, NY, US
08:30	Response evaluation Jedd D. Wolchok, New York, NY, US
08:55	Monitoring of immune response Michael Kalos, Philadelphia, PA, US
09:20	Biomarkers, tissue analysis and potential applications Jerome Galon, Paris, France
09:45	The model of breast cancer Giuseppe Curigliano, Milan, Italy
10:10	General discussion / Q&A
10:25	Coffee break
10.20	OUTIEG DIGAN
10:45/ 12:15	00.100 0100.1
10:45/	Promising therapeutic strategies
10:45/ 12:15	Promising therapeutic strategies Chair: Ton N. Schumacher, Amsterdam, Netherlands Novel approaches to molecular vaccines
10:45/ 12:15 10:45	Promising therapeutic strategies Chair: Ton N. Schumacher, Amsterdam, Netherlands Novel approaches to molecular vaccines Sebastian Kreiter, Mainz, Germany Dissecting adoptive T cell therapies
10:45/ 12:15 10:45 11:10	Promising therapeutic strategies Chair: Ton N. Schumacher, Amsterdam, Netherlands Novel approaches to molecular vaccines Sebastian Kreiter, Mainz, Germany Dissecting adoptive T cell therapies Ton N. Schumacher, Amsterdam, Netherlands Checkpoint inhibitors PD1, PDL1 vs CTLA-4

13:15/ 15:15	Integration with other therapies / combination approaches Chair: Cornelis J. Melief, Leiden, Netherlands
13:15	Surgery with focus on TILs Laszlo G. Radvanyi, Houston, TX, US
13:40	Radiotherapy <i>Dirk De Ruysscher, Leuven, Belgium</i>
14:05	Chemotherapy combinations Martin Reck, Grosshansdorf, Germany
14:30	Immunotherapy combinations Comelis J. Melief, Leiden, Netherlands
14:55	General discussion/ Q&A
15:15/ 16:00	Outlook and panel discussion Chairs: George Coukos, Lausanne, Switzerland and Rolf A. Stahel, Zurich, Switzerland
15:15	Current therapeutic options and development strategies George Coukos, Lausanne, Switzerland
15:40	Panel discussion
16:00	Closing remarks Chairs: George Coukos, Lausanne, Switzerland and Rolf A. Stabel Zurich, Switzerland

INVITED SPEAKER DISCLOSURES

Curigliano Giuseppe The De Ruysscher Dirk The Dietrich Pierre-Yves Rece Nova Galon Jerome No d Gerritsen Winald Consupe Advi Aste June Carl H. Spoi Kalos Michael Rece supp Nova Melief Cornelis J. Rece in Cappr Melero Ignacio Rece hond Sero Michielin Olivier The Nathan Paul Reci com Peters Solange The Radvanyi Laszlo G. The Reck Martin No d	author has declared no conflicts of interest author has declared no consultation fees: BMS lisclosure at time of going to press sultancy: Aglaia Biomedical Ventures. Honorarium: authors: Aglaia Biomedical Ventures. Honorarium: authors: BMS, Janssen-Cilag, Sanofi, authors: BMS, Janssen-Cilag, Sanofi, authors: BMS, Janssen-Cilag, Sanofi, authors: BMS, BMS, Janssen-Cilag, Sanofi, authors: BMS, BMS, Satra Teneous author has declared no conflicts of fees: Novartris. Consultation fees: Novartris. Other artis author has declared no conflicts of interest author has declared no consultation fees: Soo (employed sorting to consultation fees: CSO (employed sorting fees). Stock shareholder: in possession of Stock action rights author has declared no conflicts of interest author has declar
De Ruysscher Dirk Dietrich Pierre-Yves Rece Nova Galon Jerome Recritsen Winald Gerritsen Winald June Carl H. Spoi Kalos Michael Rece supp Nova Melief Cornelis J. Melero Ignacio Michielin Olivier Nathan Paul Reci com Peters Solange Radvanyi Laszlo G. The Reck Martin No deservers	author has declared no conflicts of interest ipt of grants/research supports: Amgen, Sanofi, Roche, artis. Receipt of honoraria or consultation fees: BMS lisclosure at time of going to press sultancy: Aglaia Biomedical Ventures. Honorarium: ervisory board PsytoBe. Speakers fee: J&J, BMS. sory Boards: Amgen, BMS, Janssen-Cilag, Sanofi, llas, Bayer, Merck nsored research grant and royalties from Novartis eipt of honoraria or consultation fees: Novartris. Other norts: Royalties and Licensing of Cartiq Technology to artis eipt of honoraria or consultation fees: CSO (employed SO). Stock shareholder: in possession of Stock eciation rights eipt of grants / research supports: BMS. Receipt of
Dietrich Pierre-Yves Rece Nova Galon Jerome No de Gerritsen Winald Consuper Advi Aste June Carl H. Sport Kalos Michael Rece Supp Nova Melief Cornelis J. Recein Cappr Michielin Olivier The Nathan Paul Reci com Peters Solange The Radvanyi Laszlo G. The Reck Martin No de Galor Nova Nova Nova Nova Nova Nova Nova Nova	sipt of grants/research supports: Amgen, Sanofi, Roche, artis. Receipt of honoraria or consultation fees: BMS lisclosure at time of going to press sultancy: Aglaia Biomedical Ventures. Honorarium: ervisory board PsytoBe. Speakers fee: J&J, BMS. sory Boards: Amgen, BMS, Janssen-Cilag, Sanofi, llas, Bayer, Merck ensored research grant and royalties from Novartis eipt of honoraria or consultation fees: Novartris. Other honoraria or consultation fees: CSO (employed SO). Stock shareholder: in possession of Stock eciation rights
Galon Jerome No d Galon Jerome No d Gerritsen Winald Consupe Advi Aste June Carl H. Spor Kalos Michael Rece supp Nova Melief Cornelis J. Rece in Cappr Michielin Olivier The Nathan Paul Reci com Peters Solange The Radvanyi Laszlo G. The Reck Martin No d	artis. Receipt of honoraria or consultation fees: BMS disclosure at time of going to press sultancy: Aglaia Biomedical Ventures. Honorarium: ervisory board PsytoBe. Speakers fee: J&J, BMS. sory Boards: Amgen, BMS, Janssen-Cilag, Sanofi, llas, Bayer, Merck nsored research grant and royalties from Novartis eipt of honoraria or consultation fees: Novartris. Other norts: Royalties and Licensing of Cartiq Technology to artis eipt of honoraria or consultation fees: CSO (employed SO). Stock shareholder: in possession of Stock eciation rights
Gerritsen Winald Comsuper Advit Aster June Carl H. Sport Kalos Michael Recessing Super Nova Melief Cornelis J. Recein Cappr Melero Ignacio Recein Comper Michielin Olivier The Nathan Paul Recicom Peters Solange The Radvanyi Laszlo G. The Reck Martin No design Recein Comper Nova Michielin Olivier The Reck Martin No design Recein Comper Nova Martin No design Recein Recein Martin No design Recein Recein Recein Martin No design Recein Receive Rece	sultancy: Aglaia Biomedical Ventures. Honorarium: ervisory board PsytoBe. Speakers fee: J&J, BMS. sory Boards: Amgen, BMS, Janssen-Cilag, Sanofi, llas, Bayer, Merck nsored research grant and royalties from Novartis eipt of honoraria or consultation fees: Novartris. Other norts: Royalties and Licensing of Cartiq Technology to artis eipt of honoraria or consultation fees: CSO (employed SO). Stock shareholder: in possession of Stock eciation rights
Supe Advi Aster Advi Aster June Carl H. Sport Kalos Michael Rece Supp Nova Melief Cornelis J. Rece in Cappr Melero Ignacio Rece hond Sero Michielin Olivier The Nathan Paul Reci com Peters Solange The Radvanyi Laszlo G. The Reck Martin No designed Notes Advanged	ervisory board PsytoBe. Speakers fee: J&J, BMS. sory Boards: Amgen, BMS, Janssen-Cilag, Sanofi, Illas, Bayer, Merck Insored research grant and royalties from Novartis stipt of honoraria or consultation fees: Novartris. Other corts: Royalties and Licensing of Cartiq Technology to artis Lipt of honoraria or consultation fees: CSO (employed SO). Stock shareholder: in possession of Stock eciation rights Lipt of grants / research supports: BMS. Receipt of
Kalos Michael Secsup, Nov. Melief Cornelis J. Recein Ciappr Melero Ignacio Receinon Sero Michielin Olivier The Nathan Paul Recicom Peters Solange The Radvanyi Laszlo G. The Reck Martin No description.	cipt of honoraria or consultation fees: Novartris. Other corts: Royalties and Licensing of Cartiq Technology to artis cipt of honoraria or consultation fees: CSO (employed SO). Stock shareholder: in possession of Stock eciation rights cipt of grants / research supports: BMS. Receipt of
Supp. Nova Melief Cornelis J. Rece in C. appr Melero Ignacio Rece hond Sero Michielin Olivier The Nathan Paul Reci com Peters Solange The Radvanyi Laszlo G. The Reck Martin No of	orts: Royalties and Licensing of Cartiq Technology to artis sipt of honoraria or consultation fees: CSO (employed SO). Stock shareholder: in possession of Stock eciation rights sipt of grants / research supports: BMS. Receipt of
Melero Ignacio Rece hono Sero Michielin Olivier Nathan Paul Peters Solange Radvanyi Laszlo G. The	SO). Stock shareholder: in possession of Stock eciation rights eipt of grants / research supports: BMS. Receipt of
Michielin Olivier The Nathan Paul Reci com Peters Solange The Radvanyi Laszlo G. The Reck Martin No d	
Nathan Paul Reci com Peters Solange The Radvanyi Laszlo G. The Reck Martin No d	no, Miltenyi
Peters Solange The Radvanyi Laszlo G. The Reck Martin No d	author has declared no conflicts of interest
Radvanyi Laszlo G. The Reck Martin No d	pt of grants/research supports: BMS. Participation in a pany sponsored speaker's bureau: BMS
Reck Martin No d	author has declared no conflicts of interest
	author has declared no conflicts of interest
	lisclosure at time of going to press
Robert Caroline Rece Roch	eipt of honoraria or consultation fees: BMS, Merck, ne, Novartis, GSK
Sahin Ugur The	author has declared no conflicts of interest
Schumacher Ton N. The	author has declared no conflicts of interest
	eipt of honoraria or consultation fees: Abbott, Amgen, Ilas, AZ, Genentech, Eli Lilly, Merck, Novartis, Roche
in Pe (rese	pipt of grants/research supports: Astra-Zeneca Chair prsonalised Lung Cancer Care at the Leuven University parch funding). Receipt of honoraria or consultation GSK-BIO, Merck-Serono
Wolchok Jedd D. Rece hond	eipt of grants/research supports: GSK, BMS. Receipt of oraria or consultation fees: Ziopharm, BMS, GSK, J&J